Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Annaly Capital Management capped off a robust 2025 with a fourth-quarter economic return of 8.6%, driven by a constructive fixed-income environment and growth across its core strategies. The mortgage REIT highlighted conservative leverage, a secure dividend, and strategic capital deployment as it navigates evolving market conditions.
National Fuel Gas (NFG) reported robust first-quarter earnings, driven by a 29% surge in upstream EBITDA. Executives highlighted progress on pipeline expansions, strategic hedging against volatile gas prices, and the planned acquisition of CenterPoint's Ohio utility, while reaffirming full-year guidance.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
The Singapore-listed port operator has significantly improved its capital efficiency over five years, rewarding shareholders. Analysts are now weighing whether this trend is sustainable for long-term growth.
Shares of Southwest Airlines surged nearly 19% to a four-year peak after the carrier officially ended its decades-long open seating policy, a move analysts say could significantly boost future revenue.
Kirby Corporation (NYSE: KEX) reported record annual earnings for 2025, fueled by robust free cash flow and strategic capital returns. While Q4 faced seasonal pressures, management highlighted a late-quarter rebound in inland marine and surging demand in power generation, setting the stage for what they project as a year of steady financial performance in 2026.
As regional tensions weigh on major Gulf indices, a closer look reveals resilient investment opportunities among smaller, financially sound companies. From energy giants to niche manufacturers, these picks highlight value where many fear to tread.
Dolby Laboratories (NYSE: DLB) kicked off fiscal 2026 with robust first-quarter results, exceeding its own revenue and earnings forecasts. The audio-visual technology leader credits strong deal timing and highlighted significant momentum in automotive, television, and mobile partnerships, including expanded ties with Qualcomm and major social media platforms.
Activist investment firm Tsai Capital has taken a stake in QXO, spotlighting the distributor's ambitious plan to consolidate the fragmented building products industry. The move comes as QXO's stock shows strong recent momentum despite longer-term headwinds.
Fueled by record-breaking demand for its HOKA and UGG brands, Deckers Outdoor posts a robust Q3, beating expectations. The company credits disciplined full-price selling and strategic marketplace management for driving growth across all regions, leading to an upward revision of its fiscal 2026 guidance.
As global gold prices hit historic highs, Vietnam's deep-rooted culture of gold ownership is creating starkly divided fortunes, turning traditional family loans into crushing debts while minting paper billionaires among long-term holders.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
